1020846-48-3Relevant academic research and scientific papers
Enantio- and Diastereoselective, Complete Hydrogenation of Benzofurans by Cascade Catalysis
Gallagher, Timothy,Glorius, Frank,Hu, Tianjiao,Moock, Daniel,Wagener, Tobias
supporting information, p. 13677 - 13681 (2021/05/10)
We report an enantio- and diastereoselective, complete hydrogenation of multiply substituted benzofurans in a one-pot cascade catalysis. The developed protocol facilitates the controlled installation of up to six new defined stereocenters and produces architecturally complex octahydrobenzofurans, prevalent in many bioactive molecules. A unique match of a chiral homogeneous ruthenium-N-heterocyclic carbene complex and an in situ activated rhodium catalyst from a complex precursor act in sequence to enable the presented process.
Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists
Shimada, Itsuro,Maeno, Kyoichi,Kondoh, Yutaka,Kaku, Hidetaka,Sugasawa, Keizo,Kimura, Yasuharu,Hatanaka, Ken-ichi,Naitou, Yuki,Wanibuchi, Fumikazu,Sakamoto, Shuichi,Tsukamoto, Shin-ichi
, p. 3309 - 3320 (2008/09/20)
To identify potent and selective 5-HT2C receptor agonists, a series of novel benzazepine derivatives were synthesized, and their structure-activity relationships examined. The compounds were evaluated for their 5-HT2C, 5-HT2A/s
Discovery of novel and potent retinoic acid receptor α agonists: Syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives
Yoshimura, Hiroyuki,Kikuchi, Kouichi,Hibi, Shigeki,Tagami, Katsuya,Satoh, Takashi,Yamauchi, Toshihiko,Ishibahi, Akira,Tai, Kenji,Hida, Takayuki,Tokuhara, Naoki,Nagai, Mitsuo
, p. 2929 - 2937 (2007/10/03)
In the course of our studies on retinoic acid receptor (RAR) agonists, we have designed and synthesized a series of benzofuran and benzothiophene derivatives. Some of these compounds (1a,b,e,f,j) markedly inhibited LPS- induced B-lymphocyte proliferation and exerted RARα selectivity. One of them, 4-[5-(4,7-dimethylbenzofuran-2-yl)pyrrol-2-yl]benzoic acid (1b), when orally administered significantly inhibited mouse antibody production and delayed type hypersensitivity (DTH) responses from a dose of 0.1 mg/kg.
